Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

MYGN

Myriad Genetics (MYGN)

Myriad Genetics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MYGN
DateHeureSourceTitreSymboleSociété
24/06/202422h05GlobeNewswire Inc.Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the ElectionNASDAQ:MYGNMyriad Genetics Inc
11/06/202414h00GlobeNewswire Inc.Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 CountriesNASDAQ:MYGNMyriad Genetics Inc
10/06/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
06/06/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MYGNMyriad Genetics Inc
04/06/202416h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MYGNMyriad Genetics Inc
04/06/202415h00GlobeNewswire Inc.Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier ScreenNASDAQ:MYGNMyriad Genetics Inc
03/06/202422h05GlobeNewswire Inc.Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment ToolNASDAQ:MYGNMyriad Genetics Inc
30/05/202423h55GlobeNewswire Inc.QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applicationsNASDAQ:MYGNMyriad Genetics Inc
24/05/202400h00GlobeNewswire Inc.Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingNASDAQ:MYGNMyriad Genetics Inc
16/05/202422h05GlobeNewswire Inc.New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerNASDAQ:MYGNMyriad Genetics Inc
08/05/202414h23IH Market NewsReddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in EarningsNASDAQ:MYGNMyriad Genetics Inc
08/05/202414h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MYGNMyriad Genetics Inc
07/05/202422h05GlobeNewswire Inc.Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDANASDAQ:MYGNMyriad Genetics Inc
07/05/202415h00GlobeNewswire Inc.Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessNASDAQ:MYGNMyriad Genetics Inc
30/04/202422h05GlobeNewswire Inc.Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MYGNMyriad Genetics Inc
17/04/202414h00GlobeNewswire Inc.Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorNASDAQ:MYGNMyriad Genetics Inc
16/04/202415h15GlobeNewswire Inc.New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenNASDAQ:MYGNMyriad Genetics Inc
09/04/202414h00GlobeNewswire Inc.Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingNASDAQ:MYGNMyriad Genetics Inc
22/03/202402h40GlobeNewswire Inc.Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority DateNASDAQ:MYGNMyriad Genetics Inc
20/03/202421h05GlobeNewswire Inc.Myriad Genetics Announces Patent Granted for SneakPeek® Snap DeviceNASDAQ:MYGNMyriad Genetics Inc
28/02/202414h31Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MYGNMyriad Genetics Inc
27/02/202422h05GlobeNewswire Inc.Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the FoNASDAQ:MYGNMyriad Genetics Inc
27/02/202415h15GlobeNewswire Inc.Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3NASDAQ:MYGNMyriad Genetics Inc
21/02/202422h05GlobeNewswire Inc.Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024NASDAQ:MYGNMyriad Genetics Inc
15/02/202422h05GlobeNewswire Inc.Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s HealthNASDAQ:MYGNMyriad Genetics Inc
14/02/202422h47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MYGNMyriad Genetics Inc
01/02/202415h25GlobeNewswire Inc.Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision GenomicsNASDAQ:MYGNMyriad Genetics Inc
30/01/202423h00GlobeNewswire Inc.Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of OncologyNASDAQ:MYGNMyriad Genetics Inc
29/01/202422h21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MYGNMyriad Genetics Inc
19/01/202400h10GlobeNewswire Inc.Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision GenomicsNASDAQ:MYGNMyriad Genetics Inc
 Showing the most relevant articles for your search:NASDAQ:MYGN